Pharmaceutical Technology
MARCH 17, 2023
Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. Thus, a higher risk score reflects a more hostile market access environment and drug launch in a geographical area.
Pharmaceutical Technology
JANUARY 27, 2023
On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. Cablivi stops platelets from clumping together, which prevents small clots, and can be used along with other drugs that suppress the immune system.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
AUGUST 20, 2020
Among the drugs to lose contracts were Eli Lilly schizophrenia medicine Zyprexa and Pfizer’s Viagra, the publication said. RELATED: Is Pfizer’s established drugs’ decline in China the ‘canary in the coalmine?’ Pfizer’s established drugs business started showing a decline in China back in April 2019.
Roots Analysis
JANUARY 23, 2024
Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases. The growing popularity of peptide-based drugs can be attributed to its high specificity, minimal drug-drug interactions, affinity, proven pharmacological value and favorable safety profiles.
The Pharma Data
DECEMBER 31, 2020
Reimer replaces Charlotte Russel and will be responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. Prior to that, Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector.
XTalks
JUNE 9, 2022
Still riding high on the approval of its dual-targeting GIP/GLP-1 injection Mounjaro (tirzepatide) for the treatment of type 2 diabetes, Eli Lilly continues to forage the path ahead with the drug, sharing new analyses that continues to build a strong case for it as a weight loss injection for obese patients. billion in sales by 2026.
The Pharma Data
DECEMBER 28, 2020
Prior to that, Dr. Zhang was an equity research analyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine.
Expert insights. Personalized for you.
257 
Let's personalize your content